By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Bridge to New Markets.

Zika Virus: Testing for Austria vaccine begins

logo Themis © Themis

The clinical study will focus on identifying the most suitable doses of the vaccine candidate in regard to immunogenicity, safety, and tolerability. Therefore up to 48 healthy volunteers will participate in the study and three different treatment regimens will be compared with a placebo treatment. One treatment group will receive one injection of high dose vaccine, the other two groups will receive two shots of either high dose or low dose vaccine. Results of all groups are expected within the next six months. The study will be conducted at the "Department of Clinical Pharmacology" and the "Institute of Specific Prophylaxis and Tropical Medicine" at the Medical University of Vienna, Austria.

Zika is a viral infection transmitted by mosquitoes. It originates in Asia and parts of Africa but the increase in global traveling and rising temperatures may cause it to spread into more temperate zones. Recently, the virus spread across the Pacific Ocean to the Americas, leading to the 2015/16 virus epidemic.

About Themis

Themis Bioscience GmbH develops prophylactic vaccines from the preclinical to the early clinical phase, focusing on emerging tropical infectious diseases, with initial vaccine candidates currently being developed against Chikungunya and Zika. The company's highly innovative and fully patent-protected measles virus vaccine vector technology platform, licensed from the internationally respected Institut Pasteur in Paris, forms the basis for all current vaccine candidates of the Vienna-based company.
www.themisbio.com

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • Life Sciences Wien - Ein Markt mit vielen Chancen

    28.01.2021, 10:00 - 11:30 (CET), Online Conference

  • Meet us @ HTH Styria!

    28.1.2021, 10:00 - 16:15 (CET) , Online Conference

Austria Map

Find the perfect location for your company

Vienna’s unique location at the heart of Europe makes it an important centre and very popular with the global pharmaceutical and biotechnology industry. Vienna is where Eastern Europe meets Western Europe. Businesses located at this international hub benefit from well-established infrastructures and highly-qualified professionals. The significant growth in the Life Sciences sector in Vienna over the last few years is an indicator of the momentum in the industry.

ABF Pharmaceutical Services

ABF Pharmaceutical Services
More testimonials

news from the business location Austria

Austrian government creates investment premium for investors

The economic and financial consequences of the COVID-19 crisis pose major challenges to companies. In order to strengthen the Austrian business location, the Austrian Federal Government has resolved upon a new investment promotion program for companies with a total volume of EUR 3 billion, which will be further increased, if necessary.

Support measures for companies affected by COVID-19

To stimulate the economy, either new programs may be established as a result of the draft law or existing support programs (e.g. aws, ÖHT) will be expanded. All measures introduced are intended to be applicable immediately and will be in force until the end of 2020. The measures currently introduced include the following areas:

More news All blog posts